Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
Date:7/29/2009

27.4 27.4 Legal settlements 18.8 18.8 Gain on asset sales (1.3) (1.3) Loss on securities 1.1 1.1 Income taxes (18.6) (18.6) ----- ----- Adjusted net income 288.9 298.7 Add: Interest expense on CODES, net of tax 7.9 7.9 --- --- Adjusted net income, adjusted for interest on CODES $296.8 $306.6 ====== ====== Diluted earnings per share Diluted earnings per share - GAAP $2.13 $2.21 ===== ===== Diluted earnings per share - Adjusted $2.50 $2.58 ===== ===== Diluted weighted average common Shares outstanding 118.8 118.8 ===== =====

The reconciliation table is based in part on management's estimate of net income for the year ending December 31, 2009. Watson expects certain known GAAP charges for 2009, as presented in the schedule above. Other GAAP charges that may be excluded from adjusted net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown. These GAAP charges, such as potential asset impairment charges, are dependent upon future events and valuations that have not yet been performe
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
2. Watson CFO Mark W. Durand to Take Leave of Absence
3. Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
4. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
5. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
6. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
7. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
8. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
9. Watson to Acquire Arrow Group
10. Watson Files FDA Application for Generic Mucinex(R) D
11. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Award-winning adult film ... about their experiences of female beauty, women’s emotions, fertility, female violence and sexual ... well as their relationships with other men, documenting how the power balance between ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... Anthony J. ... the Super Lawyers 2015 for his third consecutive year in a row. Through ... accomplishments of helping people. , Born in Niagara Falls, New York, Tantillo is a ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new episode of “Voices In America”, hosted ... at the topic of arthritis. There are over 100 different types of arthritis. One ... and statistics in an effort to shed light on this important topic. , Anyone ...
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety Month, and Lightning ... stickers to keep little ones' safety top of mind at all times. , Sponsored ... focus. According to the JPMA's Baby Safety Zone website, this year's theme is A ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... PRESENT e-Learning Systems, has become a leader in podiatric, surgical ... education. The Superbones Superwounds Conferences place top national speakers at the podium and ...
Breaking Medicine News(10 mins):Health News:Female Porn Director Explains Male Insecurities about Women in a New Book 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2
... , ANN ARBOR, Mich., Aug. 7 ... for drug and disease reference, patient education, and consumer health information ... , Price Chopper, in business for more than ... continues to grow in this region. It operates pharmacies in 68 ...
... relief but should be reserved for worst cases, researchers say, ... of a corticosteroid, given along with antibiotics, can relieve severe ... a new study suggests. , "In people with severe sore ... in relieving pain in 24 and 48 hours," said researcher ...
... , , , ... announced that it has been notified that a purported class action ... the Northern District of Illinois against the Company and certain of ... and February 13, 2008 the Company failed to disclose certain facts ...
... one of the errors most frequently confirmed in the ... Vinz and Johann Neu of the Arbitration Board of ... edition of Deutsches rzteblatt International (Dtsch Arztebl ... expert reports and rulings in 189 panel proceedings from ...
... , ... 6, 2009 in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a ... in the field, this is incorrect, as both studies actually demonstrate a significant improvement in ... ...
... in financing, delivery of care are needed to close ... -- Even if Congress extends health coverage to the ... everyone will have access to care -- unless payment ... experts say. , Significantly expanding coverage without reforming health-care ...
Cached Medicine News:Health News:Price Chopper Supermarkets Deploy Micromedex Solutions From Thomson Reuters as Key Component of Its Patient-Centered Care Initiatives 2Health News:Steroid Can Ease Severe Sore Throat 2Health News:Steroid Can Ease Severe Sore Throat 3Health News:Allscripts Notified of Purported Class Action Lawsuit 2Health News:Allscripts Notified of Purported Class Action Lawsuit 3Health News:Out of court settlement of malpractice claims: Incorrect treatment of bone fractures in children 2Health News:Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain 2Health News:Arizona Pain Specialists Contend Recent Vertebroplasty Studies are Misleading: Studies Actually Show it is Effective at Reducing Pain 3Health News:Expanding Health Coverage May Not Improve Access 2Health News:Expanding Health Coverage May Not Improve Access 3
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: